Immuno-Oncology

The AJMC^® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

Travis Osterman, DO, MS, FAMIA, FASCO

Leveraging AI to Optimize Precision Immunotherapy at Vanderbilt

By Maggie L. Shaw

October 25th 2024

The theme of our recent Nashville Institute for Value-Based Medicine® event was ”Bringing the Future to the Present in Cancer Care.”

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

By Alana Hippensteele

September 15th 2024

Rates of ICI-related CVAEs and myocarditis were low, but the risk of mortality following CVAEs is high, underscoring the need for monitoring and management of these effects. | Image credit: Henadzy - stock.adobe.com

Early Recognition, Action Crucial for ICI-Induced Cardiovascular Adverse Effects

By Rose McNulty

August 30th 2024

The Challenge With CAR T? It’s Not the Drug, It’s the Delivery

The Challenge With CAR T? It’s Not the Drug, It’s the Delivery

By Mary Caffrey

August 24th 2024

Jeff Patton, MD | Image: OneOncology

OneOncology Announces Deal to Acquire United Urology Group

By Mary Caffrey

August 20th 2024

ASCO 2024: Latest Data in Melanoma

Gain expert insights to the phase 3 NADINA trial and learn more about unmet needs in melanoma management with this Post Conference Perspectives.

Gain expert insights to the phase 3 NADINA trial and learn more about unmet needs in melanoma management with this Post Conference Perspectives.

More News

Abstract image of CAR T

November 23rd 2022

Drops in Serum Phosphate Levels May Help Predict Severe CRS After CAR T

Jaime Rosenberg

A new study has found that a drop in serum inorganic phosphate (iP) was an early predictor of severe cytokine release syndrome (CRS), suggesting that monitoring serum iP levels could help promote safer management of the most common toxicity associated with chimeric antigen receptor (CAR) T-cell therapy.

Stephen M. Schleicher, MD, MBA, Tennessee Oncology

November 14th 2022

Dr Stephen Schleicher: We Need to Focus More on Financial Toxicity

Maggie L. Shaw Mary Caffrey

Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, addresses the “huge problem” of financial toxicity among patients with cancer, which can be attributed in part to both the high price of targeted treatments and even from ordering only necessary testing.

graphic depicting research

November 8th 2022

Researchers Provide Management Recommendations for CRS, Other Toxicities of CAR T

Jaime Rosenberg

While chimeric antigen receptor (CAR) T-cell therapy has offered a new option and improved outcomes for patients with advanced hematologic malignancies, the treatment approach has been associated with toxicities such as cytokine release syndrome (CRS), neurotoxicity, and hematotoxicity.

CAR T

October 25th 2022

Are NK-Cell–Based Treatments the Next Approach in Immuno-Oncology?

Jaime Rosenberg

Highlighting their ability to quickly destroy malignant cells without antigen specificity, natural killer (NK) cells have been identified as an opportunity for use, particularly in cases where T cells are not effective.

Combination of Tremelimumab and Durvalumab Approved by FDA for Unresectable Liver Cancer

October 24th 2022

Combination of Tremelimumab and Durvalumab Approved by FDA for Unresectable Liver Cancer

A dual immunotherapy option of tremelimumab, sold as Imjudo, in combination with durvalumab, sold as Imfinzi, was approved by the FDA Monday for the treatment of adult patients with unresectable hepatocellular carcinoma, the most common type of liver cancer.

Image of biotechnology innovation

October 22nd 2022

Identifying ASCT-Ineligible Patients Who Could Benefit From CAR T-Cell Treatment

Jaime Rosenberg

Data suggest that the technology may be an option for patients who are ineligible for autologous stem cell transplantation (ASCT) based on certain patient characteristics, prior treatments, stem cell availability, or tumor chemosensitivity.

At Last, Artificial Intelligence Is Transforming Cancer Drug Discovery and Development

October 20th 2022

At Last, Artificial Intelligence Is Transforming Cancer Drug Discovery and Development

Dietmar Berger, MD, PhD

Review Underscores Potential and Obstacles of Universal CAR T-Cell Therapy

October 15th 2022

Review Underscores Potential and Obstacles of Universal CAR T-Cell Therapy

Despite the obstacles and risks, the review authors conclude that universal chimeric antigen receptor (CAR) T-cell therapy has the potential to play a key role and mitigate some of the limitations associated with autologous CAR T-cell therapy in cancer treatment.

CAR T

October 14th 2022

Advances and Limitations in CD20-Targeted CAR T-Cell Therapy

The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research.

Kidneys

September 30th 2022

CAR T-Cell Therapy Outcomes Are Not Impacted by Baseline Renal Function, Study Finds

Renal outcomes and chimeric antigen receptor (CAR) T-cell therapy efficacy were unaffected by baseline renal status in a cohort of patients with diffuse large B cell lymphoma, but acute kidney injury during treatment was associated with worse clinical outcomes.

Image of cancer cells

September 17th 2022

Myeloid Cells Hold Promise as Cancer Immunotherapy Targets, Review Says

The review highlights current strategies for myeloid cell targeting and novel agents targeting myeloid cells for cancer treatment.

Image of immuno-oncology

September 7th 2022

Neurofilament Light Chain Levels May Indicate Risk of CAR T–Related Neurotoxicity

A significant portion of patients who receive chimeric antigen receptor (CAR) T-cell therapy experience immune effector cell–associated neurotoxicity syndrome, and this recent study suggests neurofilament light chain protein levels may hold promise as a biomarker to identify at-risk patients.

targeted cancer therapy

September 2nd 2022

Which Chemo-IO Combo Is Optimal in First-line Esophageal Cancer?

Jaime Rosenberg

The review of 5 phase 3 randomized controlled trials found that overall, the combination treatments improved survival outcomes while eliciting more, but manageable, side effects.

syringe in a bag

August 30th 2022

Replacing White Bagging Mandates With Market Competition Will Improve Patient Outcome

Wayne Winegarden, PhD

Wayne Winegarden, PhD, of the Pacific Research Institute, explains the harm that white bagging policies cause health systems and how replacing them with new measures to boost market competition could help patients.

Image of immunotherapy

August 21st 2022

CAR T-Cell Therapy Outcomes Likely Not Influenced by Race/Ethnicity, Obesity

Jaime Rosenberg

Researchers studied data from 5 phase 1 studies that took place between 2012 and 2021, comprising 139 infusions among patients with B-cell acute lymphoblastic leukemia who received chimeric antigen receptor (CAR) T-cell treatment.

Image of a woman with breast cancer

August 14th 2022

Targeted Treatment for Breast Cancer Explored in New Study

Jaime Rosenberg

Despite advances made against the disease, researchers note that breast cancer still remains a top cause of cancer-related mortality in women around the world.

Image of a target

August 9th 2022

CAR T Outcomes Not Significantly Affected by rrDLBCL Subgroup

Jaime Rosenberg

With 40% of patients with diffuse large B-cell lymphoma experiencing relapsed or refractory disease (rrDLBCL), researchers highlighted the promise of chimeric antigen receptor (CAR) T-cell therapy for these patients.

lymphoma

August 4th 2022

Three CAR T-Cell Trials, 2 Outcomes, for Second-line LBCL Therapy

Jaime Rosenberg

Both the ZUMA-7 trial for axicabtagene ciloleucel—approved for second-line treatment earlier this year—and the TRANSFORM trial for lisocabtagene maraleucel showed significant improvement over standard of care for large B cell lymphoma (LBCL), while the BELINDA trial for tisagenlecleucel did not.

Amila Patel, PharmD

July 29th 2022

Dr Amila Patel Highlights Findings on Disparities in Immunotherapy Delivery

Laura Joszt, MA

Data presented at the American Society of Clinical Oncology annual meeting found non-White patients are less likely to receive immunotherapy for head and neck cancer, said Amila Patel, PharmD, chief clinical officer, Navigating Cancer.

CAR T image

July 25th 2022

Fungal Infections Rarer, Linked With Worse Prognosis in Patients Receiving CAR T-Cell Therapy

Jaime Rosenberg

Overall, infections occurred in 18.42% of cases and typically occurred within the first month, significantly dropping from then on.

Melissa L. Johnson, MD

July 22nd 2022

Dosing Study of Modakafusp Alfa Shows Promise in Solid Tumors; Tests Planned With Checkpoint Inhibitors

Manish Patel, MD

July 22nd 2022

Lucitanib With Nivolumab Sees Responses in Gynecological Cancer Treatment

Frederick L. Locke, MD

July 22nd 2022

Data Indicate Lower Response Rates to Axi-cel Among Black Patients

ASCO Spotlight With Kim A. Reiss, MD, on CAR Macrophages and Other Developments in Pancreatic Cancer

July 21st 2022

ASCO Spotlight With Kim A. Reiss, MD, on CAR Macrophages and Other Developments in Pancreatic Cancer

Maggie L. Shaw Hayley Virgil

Kim A. Reiss, MD, assistant program director, assistant professor of medicine, Hospital of the University of Pennsylvania, Philadelphia, discusses 2 abstracts presented during ASCO.

Inspection Delays Prompt FDA Deferral on Tislelizumab in Second-line ESCC

July 14th 2022

Inspection Delays Prompt FDA Deferral on Tislelizumab in Second-line ESCC

Nicolas K. Trad

July 7th 2022

Patients With Cancer Face Major Financial Roadblocks, Not All Concerning Out-of-Pocket Costs

Abstracts presented at this year's American Society of Clinical Oncology Annual meeting detailed the financial hardships many patients with cancer face, including those related to high-deductible health plans and clinical trial participation.

Zahra Mahmoudjafari, PharmD, BCOP

July 2nd 2022

Dr Zahra Mahmoudjafari Explains How Payers Can Better Manage CAR T Costs, Increase Access

Skylar Jeremias Lindsey Mulrooney

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, explains some of the strategies that payers can use to improve cost management and increase patient access related to chimeric antigen receptor T-cell (CAR T) therapies.

Zahra Mahmoudjafari, PharmD, BCOP

June 23rd 2022

Dr Zahra Mahmoudjafari Previews CAR T Therapies Coming Down the Pipeline

Skylar Jeremias Lindsey Mulrooney

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.

COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”

June 23rd 2022

COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”

Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.

Image of a broken heart

June 17th 2022

Major Adverse Cardiac Events Related to ICI Treatment Explored in New Study

Major adverse cardiac events are rare but serious in patients treated with immune checkpoint inhibitors (ICIs), and increased awareness is crucial to identify and treat these conditions in a timely manner.

<1 2 3 4 5 6 7 8 9

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions